Faculty

Back to Index
Anil Tulpule, MD
Associate Professor of Clinical Medicine
Medicine
NOR 3458 Health Sciences Campus Los Angeles
+1 323 865 3927

Overview

Dr. Tulpule began his medical education and career in his native India before coming to Southern California on a fellowship in medical oncology at the Keck School of Medicine. After completion of his first USC fellowship, Dr. Tulpule was granted an additional fellowship in the Department of Hematology where he is currently holds an assistant professor appointment. Dr. Tulpule remains active in AIDS research, including a ten year affiliation with the government sponsored AIDS-Related Malignancy Working Group at the National Cancer Institute.

He has received over fifteen research grants on a number of hematology related subjects and his work has been published in many noted medical journals. Dr. Tulpule is a member of the LAC+USC Medical Center’s Internal Review Board and has a role in determining the ethical implications of the center’s research studies. His dedication to ethical practices also includes a membership of USC Norris Comprehensive Cancer Center’s Patient’s Rights Committee.

Publications

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clin Lymphoma Myeloma Leuk. 2017 Jan 10. View in: PubMed

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. 2016 Dec 02. View in: PubMed

p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression: A Single Institutional Clinicopathologic Study. Am J Clin Pathol. 2014 Apr; 141(4):593-604. View in: PubMed

Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol. 2013 Jan 1; 31(1):58-64. View in: PubMed

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010 Dec; 11(12):1149-59. View in: PubMed

Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010 Aug 15; 116(16):3969-77. View in: PubMed

Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood. 2010 Jul 15; 116(2):297-305. View in: PubMed

KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood. 2010 Jan 28; 115(4):887-95. View in: PubMed

Bendamustine therapy in chronic lymphocytic leukemia. Expert Opin Pharmacother. 2009 Jul; 10(10):1687-98. View in: PubMed

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008 Sep 20; 26(27):4473-9. View in: PubMed

Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer. 2006 Oct 15; 107(8):1909-17. View in: PubMed

Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma. 2006 Jul; 7(1):59-64. View in: PubMed

Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol. 2006 Apr 10; 24(11):1712-9. View in: PubMed

Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol. 2005 Nov 20; 23(33):8477-82. View in: PubMed

Multidrug resistance in AIDS-related lymphoma. Curr Opin Oncol. 2005 Sep; 17(5):466-8. View in: PubMed

AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005 Jul 1; 23(19):4430-8. View in: PubMed

Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10; 23(5):990-8. View in: PubMed

Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium. Blood. 2005 Feb 1; 105(3):1310-8. View in: PubMed

Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol. 2004 Jul 1; 22(13):2662-70. View in: PubMed

Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study. Invest New Drugs. 2004 Jan; 22(1):63-8. View in: PubMed

Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002 Jul 1; 95(1):147-54. View in: PubMed

Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection. Cancer. 2002 Mar 1; 94(5):1500-6. View in: PubMed

Multidrug resistance (MDR-1) expression in AIDS-related lymphomas. Leuk Res. 2002 Feb; 26(2):121-7. View in: PubMed

High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr. 2001 Dec 15; 28(5):416-21. View in: PubMed

Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma. Clin Cancer Res. 2001 Sep; 7(9):2693-702. View in: PubMed

Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer. 2001 Jul; 37(10):1288-95. View in: PubMed

Incidence and management of AIDS-related lymphoma. Oncology (Williston Park). 2001 May; 15(5):629-39; discussion 639-40, 645-6. View in: PubMed

Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol. 2001 Apr; 12(4):457-62. View in: PubMed

Evolving characteristics of AIDS-related lymphoma. Blood. 2000 Dec 15; 96(13):4084-90. View in: PubMed

Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1; 96(9):3188-94. View in: PubMed

Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr. 2000 Aug 15; 24(5):444-50. View in: PubMed

Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000 Feb; 18(4):716-23. View in: PubMed

AIDS-related lymphoma. Blood Rev. 1999 Sep; 13(3):147-50. View in: PubMed

Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol. 1999 Jun; 17(6):1876-83. View in: PubMed

Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma. Cancer. 1998 Dec 1; 83(11):2370-6. View in: PubMed

Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. J Clin Oncol. 1998 Oct; 16(10):3369-74. View in: PubMed

Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma. Curr Opin Oncol. 1998 Sep; 10(5):413-21. View in: PubMed

AIDS-Related malignancies. Prim Care. 1998 Jun; 25(2):473-82. View in: PubMed

Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma. J Natl Cancer Inst. 1997 Dec 3; 89(23):1797-802. View in: PubMed

Treatment of epidemic (AIDS-related) Kaposi's sarcoma. Curr Opin Oncol. 1997 Sep; 9(5):433-9. View in: PubMed

Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. J Clin Oncol. 1997 Mar; 15(3):1094-103. View in: PubMed

Interleukin-4 in the treatment of AIDS-related Kaposi's sarcoma. Ann Oncol. 1997 Jan; 8(1):79-83. View in: PubMed

The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med. 1996 Oct 24; 335(17):1261-9. View in: PubMed

Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time. Cancer. 1996 Aug 1; 78(3):517-26. View in: PubMed

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol. 1995 Apr; 13(4):996-1003. View in: PubMed

Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol. 1995; 37(1-2):32-8. View in: PubMed

All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study. Leukemia. 1994; 8 Suppl 3:S26-32. View in: PubMed

Intraperitoneal 5-fluoro-2'-deoxyuridine with escalating doses of leucovorin: pharmacology and clinical tolerance. Invest New Drugs. 1994; 12(3):197-206. View in: PubMed

Powered bySC CTSI